New York, May 20, 2026, 13:02 (EDT)
NervGen Pharma Corp. shares rose nearly 4% in midday Nasdaq trading on Wednesday, as investors weighed a fresh quarterly update that put the spinal-cord-injury drug developer closer to starting its late-stage RESTORE trial. The stock traded at $3.70, up 3.93%, after moving between $3.58 and $3.75, with about 59,940 shares changing hands.
The move matters now because NervGen is shifting from regulatory alignment to execution. The company said this week it had reached agreement with the U.S. Food and Drug Administration on RESTORE, a registrational study — a trial designed to support a future approval filing — for NVG-291 in chronic tetraplegia, paralysis affecting all four limbs. Chief Executive Adam Rogers said NervGen was “firmly in execution mode,” with site activation underway and study initiation still targeted for mid-2026. GlobeNewswire
That gives the stock a cleaner near-term setup, but not an easy one. For a small, clinical-stage biotech, the next trade is likely to hinge less on quarterly loss figures and more on whether the company can start RESTORE, fund it, enroll it and produce data strong enough to keep regulators and investors onside.
The next clinical readout is also near. NervGen said independent, blinded biomechanical gait analyses from the CONNECT SCI study remain underway, with results expected in the second quarter; “blinded” means reviewers do not know who received the drug or placebo, a way to reduce bias when judging results. GlobeNewswire
The balance sheet is the rub. NervGen’s SEC-filed management discussion showed C$16.56 million in cash and cash equivalents at March 31, operating cash use of C$8.20 million in the quarter, and management’s view that current cash would fund operations only through the second quarter of 2026 unless spending is cut or delayed. It said additional capital would be needed to meet its goals, including the Phase 3 trial.
The broader market helped the tone. Wall Street’s main indexes rose at midday, led by chip stocks ahead of Nvidia results, with the Nasdaq up about 1.4%, Reuters reported.
NervGen is now mainly a Nasdaq story. The company began trading on Nasdaq in January under NGEN and later voluntarily delisted from the TSX Venture Exchange, saying the U.S. listing would remain the trading venue for common shares and reduce duplicative costs.
Competition in spinal cord injury is narrow, but not absent. Lineage Cell Therapeutics is enrolling a study of OPC1, an allogeneic oligodendrocyte progenitor cell therapy — cells intended to support or replace damaged spinal-cord cells — in both subacute and chronic spinal cord injury patients, a different approach from NervGen’s drug candidate.
Specialists have taken notice of NervGen’s data, though the field has a long record of disappointment. Armin Curt, clinical director of the Accelerated Translational Program at Wings for Life, said in April that NVG-291 represented the “most compelling clinical evidence” he had seen for a pharmacologic treatment in chronic tetraplegia, while noting the RESTORE design’s focus on hand function. GlobeNewswire
But FDA alignment is not approval, and a Phase 3 plan is not financing. If the gait analysis disappoints, RESTORE start-up slips, or a capital raise comes on weak terms, Wednesday’s gain could fade quickly. The company itself has warned that clinical development plans depend on additional funding and that trial uncertainty remains a material risk.
For now, the stock is trading on a tighter clock: data expected this quarter, trial start targeted for mid-year, and cash runway measured in months, not years.
